Symptomatic and disease-modifying therapy pipeline for alzheimer’s disease: towards a personalized polypharmacology patient-centered approach

HIGHLIGHTS

• who: Xavier Moratu00f3 et al. from the Universitat Internacional de Catalunya, Barcelona, Spain have published the research: Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimeru2019s Disease: Towards a Personalized Polypharmacology Patient-Centered Approach, in the Journal: (JOURNAL) of 31/08/2021

SUMMARY

Studies analyzing the amino-terminus of the Aβ in the AD brain showed that Aβ3(pGlu)-42 is an important component of the Aβ deposited in senile plaques of the AD brain, constituting approximately 25% of the total Aβ42. The initial rationale for TPE in AD was that the . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or E-mail:

If you don't have an account, you can create one here.